The product label for generic ezetimibe/ medication simvastatin (Vytorin drug, Merck/Schering-Plough) may now show that it was more effective than generic rosuvastatin calcium (Crestor, AstraZeneca) in lowering low-density lipoprotein-cholesterol levels at all doses that were compared. In a study of 2,959 patients, high cholesterol levels were reduced by 52% to 61% with Vytorin 10/20 to [...]
The FDA has approved ciclesonide nasal spray (Omnaris, Altana Pharma), a corticosteroid for treating nasal symptoms associated with seasonal and perennial allergic rhinitis (hay fever) in adults and in children 12 years of age and older.
The precise mechanism of action is unknown, although corticosteroids suppress the immune response.
requip 2 mg
The safety and efficacy of the [...]
The FDA has approved two additional uses for rituximab (Rituxan, Genen-tech/Biogen Idec) for patients with CD20-positive, B-cell non-Hodgkin’s lym-phoma (NHL): as a first-line treatment of previously untreated patients with fol-licular NHL in combination with cyclo-phosphamide, vincristine, and predni-solone (CVP) chemotherapy, and as a treatment for low-grade NHL in patients with stable disease or who have [...]
Coagulation factor VIIa (recombinant) (NovoSeven, Novo Nordisk) is the first recombinant therapy to be approved for the treatment of bleeding episodes and for the prevention of bleeding in patients with acquired hemophilia who are undergoing invasive surgical procedures.
First introduced in 1999, NovoSeven is currently indicated for the treatment of bleeding episodes in hemophilia A or [...]
Posaconazole oral suspension (Noxafil, Schering-Plough) is now approved for patients with oropharyngeal candi-diasis, including infections refractory to itraconazole and/or fluconazole.
cheap celebrex
Sitagliptin generic phosphate (Januvia, Merck), the first diabetes treatment approved in a new class of drugs known as DDP-4 inhibitors, enhances the body’s own ability to lower elevated blood glucose levels.
The FDA approved the tablets for use in addition to diet and exercise to improve blood sugar levels in patients with type-2 diabetes; the drug [...]
The FDA has approved an expanded indication for the human monoclonal antibody adalimumab (Humira, Abbott) that includes inhibiting structural joint damage and improving physical function in patients with psoriatic arthritis (PsA). This indication is in addition to the approval for PsA that was granted in October 2005.
This product is also approved for moderate-to-severe rheumatoid arthritis [...]
